智通财经APP讯，医渡科技(02158)发布公告，该公司于2025年9月26日斥资199.92万港元回购35.3万股股 份，每股回购价格为5.57-5.69港元。 ...

FF305 (註7) (i) 上市發行人已收取其在是次股份發行或庫存股份出售或轉讓應得的全部款項； 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 醫渡科技有限公司 呈交日期： 2025年9月26日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | 於香港聯交所上市 | 是 | | | 證券代號 (如上市) | 02158 | 說明 | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | 庫存股份變動 | | | | | 事件 | ...

Core Viewpoint - Yidu Technology (2158.HK) shares increased by 5.91% to HKD 6.09 following the announcement of a significant project win in clinical research [1] Group 1: Company Developments - Yidu Technology's affiliate, Tianjin Happy Life Technology Co., Ltd., won a bid for the Phase III clinical research project of the human nerve growth factor (SMR001) eye drops from Shandong Yandu Biotechnology Co., Ltd. The total project amount is approximately CNY 55.82 million [1] - The company utilizes its proprietary core algorithm engine, YiduCore, to create a "data-algorithm-scenario" closed-loop system, enabling efficient innovation and low-cost scalable applications of AI technology [1] Group 2: Industry Impact - The implementation of AI technology is driving intelligent decision-making across the entire healthcare ecosystem, which includes medicine, pharmaceuticals, insurance, and patients [1]

Group 1 - The stock of Yidu Tech (02158.HK) increased by over 5% on September 24, reaching a rise of 5.39% to a price of 6.06 HKD [1] - The trading volume for Yidu Tech was reported at 74.9734 million HKD [1]

Core Viewpoint - Yidu Technology (02158) shares increased by over 5%, currently up 5.39% at HKD 6.06, with a trading volume of HKD 74.9734 million [1] Group 1: Company Developments - Yidu Technology announced that its affiliate, Tianjin Happy Life Technology Co., Ltd., won a bid for the Phase III clinical research project of the human nerve growth factor (SMR001) eye drops from Shandong Yandu Biotechnology Co., Ltd., with a total project value of approximately RMB 55.82 million [1] - The company positions itself as a driver of AI medical transformation in China, leveraging its self-developed core algorithm engine, YiduCore, to create a "data-algorithm-scenario" closed-loop system [1] Group 2: Industry Impact - Yidu Technology's innovations enable high-efficiency and low-cost scalable applications of AI technology, facilitating intelligent decision-making across the entire healthcare ecosystem, including "medicine-insurance-patients" [1]

Core Viewpoint - Yidu Technology (02158) has seen a stock price increase of over 5%, currently trading at 6.06 HKD with a transaction volume of 74.9734 million HKD, following the announcement of a significant project win [1] Company Summary - Yidu Technology's subsidiary, Tianjin Happy Life Technology Co., Ltd., has won a bid for the Phase III clinical research project of the human nerve growth factor (SMR001) eye drops for Shandong Yandu Biotechnology Co., Ltd., with a total project value of approximately 55.82 million RMB [1] - The company positions itself as a driver of AI transformation in healthcare, utilizing its self-developed core algorithm engine, YiduCore, to create a "data-algorithm-scenario" closed-loop system [1] - This system enables efficient innovation and low-cost scalable applications of AI technology, empowering intelligent decision-making across the entire healthcare ecosystem, including medicine, insurance, and patients [1]

Group 1 - The core point of the article is that Medu Technology announced that its affiliate, Tianjin Happy Life Technology Co., Ltd., has won a bid for a Phase III clinical research project for the recombinant human nerve growth factor (SMR001) eye drops from Shandong Yandu Biotechnology Co., Ltd. [1] - The total amount of the project is approximately 55.82 million RMB [1]

作为中国AI医疗变革驱动者，医渡科技秉承"使精准医疗惠及每一个人"的使命，打造专业、高效、精准 且普惠的医学人工智能产品与解决方案。基于公司自主研发的核心算法引擎YiduCore，医渡科技构 建"数据-算法-场景"飞轮闭环，实现了AI技术的高效率创新、低成本规模化应用，推动智能决策赋 能"医-药-险-患者"全产业链生态。 AI医疗的核心是通过提升医学证据质量与生成效率，优化研发、诊断及治疗流程，最终实现更安全、 更优质、更可及的医疗服务。医渡科技持续提升医疗服务效率与可及性，让医生拥有更精准高效的决策 工具，让药企缩短分子到患者距离，让患者享有更可负担的精准诊断和治疗，让公共系统获得更科学的 支撑。医疗AI的价值，体现在对每一个个体生命的尊重与对健康福祉的守护。 医渡科技(02158)公布，近期，公司联属公司天津开心生活科技有限公司中标山东衍渡生物科技有限公 司重组人神经生长因子(SMR001)滴眼液Ⅲ期临床研究项目，项目总金额约为人民币5582万元。 ...

Core Insights - Yidu Technology (02158) announced that its subsidiary, Tianjin Happy Life Technology Co., Ltd., won a bid for the Phase III clinical research project of recombinant human nerve growth factor (SMR001) eye drops from Shandong Yandu Biotechnology Co., Ltd., with a total project amount of approximately RMB 55.82 million [1] Company Overview - Yidu Technology is positioned as a driver of AI medical transformation in China, with a mission to make precision medicine accessible to everyone [1] - The company develops professional, efficient, precise, and inclusive medical AI products and solutions based on its proprietary core algorithm engine, YiduCore [1] AI Medical Value Proposition - The core of AI in healthcare is to enhance the quality and efficiency of medical evidence, optimizing research, diagnosis, and treatment processes to ultimately provide safer, higher-quality, and more accessible medical services [1] - Yidu Technology aims to improve the efficiency and accessibility of medical services, equipping doctors with precise and efficient decision-making tools, shortening the distance from molecules to patients for pharmaceutical companies, and providing patients with affordable precision diagnosis and treatment [1] - The value of medical AI is reflected in the respect for individual lives and the safeguarding of health and well-being [1]

Core Viewpoint - Yidu Technology (02158) announced that its affiliate Tianjin Happy Life Technology Co., Ltd. won a bid for the Phase III clinical research project of recombinant human nerve growth factor (SMR001) eye drops from Shandong Yandu Biotechnology Co., Ltd., with a total project amount of approximately RMB 55.8176 million [1] Group 1 - Yidu Technology aims to drive AI medical transformation in China, adhering to the mission of making precision medicine accessible to everyone [1] - The company has developed a core algorithm engine, YiduCore, to create a "data-algorithm-scenario" closed-loop, enabling efficient innovation and low-cost scalable applications of AI technology [1] - The value of medical AI is reflected in respecting individual lives and safeguarding health and well-being [1] Group 2 - The core of AI in healthcare is to enhance the quality and efficiency of medical evidence, optimizing research, diagnosis, and treatment processes [1] - Yidu Technology continuously improves the efficiency and accessibility of medical services, providing doctors with precise decision-making tools and enabling pharmaceutical companies to shorten the distance from molecules to patients [1] - Patients benefit from more affordable precision diagnosis and treatment, while public systems receive more scientific support [1]